Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 149-158

  Sieber, Sebastian ^a   Gdynia, Georg ^a   Roth, Wilfried ^a   Bonavida, Benjamin ^b   Efferth, Thomas ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Artemisia annua; Cancer; Chemotherapy; Immune therapy; Natural products; Pharmacognosy; Traditional Chinese medicine

Indexed keywords

ANTIOXIDANT; ARTESUNATE; CATALASE; FAS ANTIGEN; GLUTATHIONE TRANSFERASE; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; RITUXIMAB; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR YY1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CHEMOSENSITIZATION; CONTROLLED STUDY; DETOXIFICATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD95; ANTIMALARIALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARTEMISININS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CATALASE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LYMPHOMA, B-CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SP1 TRANSCRIPTION FACTOR; SUPEROXIDE DISMUTASE; YY1 TRANSCRIPTION FACTOR;

EID: 67649442512     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000323     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonhard JE, Raab R, Newman RA, Hanna N and Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445, 1994.
3. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A and Dallaire BK: Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26: 66-73, 1999.
4. Hennessy BT, Hanrahan EO and Daly PA: Non-Hodgkin lymphoma: an update. Lancet Oncol 5: 341-352, 2004.
5. Demidem A, Lam T, Alas S, Hariharan K, Hanna N and Bonavida B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitises a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharmaceut 12: 177-186, 1997.
6. Alas S, Ng C-P and Bonavida B: Rituximab modifies the cisplatin-mitochondrial signalling pathway, resulting in apoptosis in cisplatin-resistant Non-Hodgkin's lymphoma. Clin Cancer Res 8: 836-845, 2002.
7. MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 23: 3530-3540, 2004.
8. Van der Kolk LE, Evers LM, Omene C, Lens SMA, Lederman S, van Lier RAW, van Oers MHJ and Eldering E: CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 16: 1735-1744, 2002.
9. Jazirehi AR and Bonavida B: Cellular and molecular signal transduction pathways modulated by Rituximab (rituxan, anti-CD20mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24: 2121-2142, 2005.
10. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H and Bonavida B: Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 8: 8114-8127, 2005.
11. Vega MI, Jazirehi AR, Huerta-Yepez S and Bonavida B: Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 175: 2174-2183, 2005.
12. Efferth T, Rücker G, Falkenberg M, Manns D, Olbrich A, Fabry U and Osieka R: Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 46: 196-200, 1996.
13. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773, 2001.
14. Efferth T: Mechanistic perspectives for 1,2,4-trioxanes in anticancer therapy. Drug Resist Update 8: 85-97, 2005.
15. Efferth T: Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 7: 407-421, 2006.
16. Efferth T: Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med 73: 299-309, 2007.
17. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH and Efferth T: Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE 2: e798, 2007.
18. Efferth T, Olbrich A and Bauer R: mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether and artemether. Biochem Pharmacol 64: 617-623, 2002.
19. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD and Funk JO: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64: 382-394, 2003.
20. Anfosso L, Efferth T, Albini A and Pfeffer U: Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 6: 269-278, 2006.
21. Efferth T, Ramirez T, Gebhart E and Halatsch ME: Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67: 1689-1700, 2004.
22. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E and Davey R: Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 28: 160-168, 2002.
23. Dell'Eva R, Pfeffer U, Vené R, Anfosso L, Forlani A, Albini A and Efferth T: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 68: 2359-2366, 2004.
24. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A and Schuler G: Artesunate in the treatment of metastatic uveal melanoma - first experiences. Oncol Rep 14: 1599-1603, 2005.
25. Alas S and Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-Non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitisation to cytotoxic drugs. Cancer Res 61: 5137-5144, 2001.
26. Alas S, Emmanouilides C and Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitisation of B-cell Non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7: 709-723, 2001.
27. 90Y-labeled HLA-DR antibodies. Clin Cancer Res 11 (Suppl. 19): S7075-S7079, 2005.
28. Nicoletti I, Migliorati G, Pagliacci MC and Ricardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
29. Friesen C, Fulda S and Debatin KM: Cytotoxic drugs and the CD95 pathway. Leukemia 13: 1854-1858, 1999.
30. Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Update 7: 97-110, 2004.
31. 2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha-induced cytotoxicity. J Biol Chem 276: 8918-8923, 2001.
32. Jazirehi AR, Gan XH, De Vos S, Emmanouilides C and Bonavida B: Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating dactor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2: 1183-1193, 2003.
33. Utz PJ and Anderson P: Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ 7: 589-602, 2000.
34. Black AR, Black JD and Azizkhan-Clifford J: Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188: 143-160, 2001.
35. Lee JY, Huerta-Yepez S, Vega M, Baritaki S, Spandidos DA and Bonavida B: The NO TRAIL to YES TRAIL in cancer therapy (Review). Int J Oncol 31: 685-691, 2007.
36. Chan H, Bartos DP and Owen-Schaub LB: Activation-dependent transcriptional regulation of the human fas promoter requires NF-kB p50-p65 recruitment. Mol Cell Biol 19: 2098-2108, 1999.
37. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA and Bonavida B: Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 6: 1387-1399, 2007.
38. Stel AJ, Ten Cate B, Jacobs S, Kok JW, Spierings DC, Dondorff M, Helfrich W, Kluin-Nelemans HC, De Leij LF, Withoff S and Kroesen BJ: Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 178: 2287-2295, 2007.
39. Efferth T, Briehl MM and Tome ME: Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol 23: 1231-1235, 2003.
40. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Häfer R, Stamminger T, Oesch F, Kaina B and Marschall M: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 37: 998-1009, 2004.
41. Efferth T, Giaisi M, Merling A, Krammer PH and Li-Weber M: Artesunate induces ROS-mediated apoptosis in Doxorubicin-resistant T leukemia cells. PLoS ONE 2: e693, 2007.
42. Martins NM, Santos NA, Curti C, Bianchi ML and Santos AC: Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 28: 337-344, 2008.
43. Efferth T and Volm M: Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo 19: 225-232, 2005.
44. Morrow CS, Cowan KH and Goldsmith ME: Structure of the human genomic glutathione S-transferase-pi gene. Gene 75: 3-11, 1989.
45. Wan XS, Devalaraja MN and St. Clair DK: Molecular structure and organization of the human manganese superoxide dismutase gene. DNA Cell Biol 13: 1127-1136, 1994.
46. Van Remmen H, Williams MD, Yang H, Walter CA and Richardson A: Analysis of the transcriptional activity of the 5′-flanking region of the rat catalase gene in transiently transfected cells and in transgenic mice. J Cell Physiol 174: 18-26, 1998.
47. Yeh CC, Wan XS and St. Clair DK: Transcriptional regulation of the 5′ proximal promoter of the human manganese superoxide dismutase gene. DNA Cell Biol 17: 921-930, 1998.
48. Nenoi M, Ichimura S, Mita K, Yukawa O and Cartwright IL: Regulation of the catalase gene promoter by Sp1, CCAAT-recognizing factors, and a WT1/ Egr-related factor in hydrogen peroxide-resistant HP100 cells. Cancer Res 61: 5885-5894, 2001.
49. Xu Y, Porntadavity S and St. Clair DK: Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). Biochem J 362: 401-412, 2002.